Korsana Completes Reverse Merger with Cyclerion, Raises $380M, Begins Trading as KRSA
Summary
Korsana Biosciences completed its reverse merger with Cyclerion Therapeutics and a concurrent $380M private placement, emerging with ~$475M in cash and a Nasdaq listing under ticker KRSA. The combined company will advance lead Alzheimer's candidate KRSA-028 toward Phase 1 data in mid-2027.
Key Events · M&A and Partnerships · CYCN
-
Reverse Merger Closes
Korsana Biosciences completed its reverse merger with Cyclerion Therapeutics on September 8, 2026. Korsana securityholders own 98.83% of the combined company; Cyclerion legacy holders retain 1.17% plus CVRs tied to legacy asset sales.
-
$380M Pre-Closing Financing
Korsana raised $380.0M in gross proceeds from 140,516,748 shares of common stock and 20,171,986 pre-funded warrants, led by Fairmount and Venrock with participation from General Atlantic, TCGX, Wellington, RA Capital, and others.
-
Pro-Forma Cash of ~$475M
Post-transaction cash and cash equivalents of approximately $475 million are expected to fund operations into 2029, including through multiple clinical milestones for KRSA-028.
-
New Leadership Team
Jonathan Violin appointed CEO and President, Mark Vignola as CFO, Matthew Leoni as CMO. Six-member board includes Tomas Kiselak as Chair; four preferred directors hold approximately 86% of board voting power.
Analysis · CYCN · Life Sciences
The reverse merger between Korsana Biosciences and Cyclerion Therapeutics closed on September 8, 2026, transforming a shell company with $1.4M in cash into a well-capitalized Alzheimer's-focused biotech with approximately $475M in pro-forma cash. The $380M pre-closing financing was led by Fairmount and Venrock, with participation from General Atlantic, TCGX, Wellington, RA Capital, and other leading life-science investors. Korsana securityholders now own 98.83% of the combined company, with Cyclerion legacy holders retaining 1.17% plus contingent value rights tied to legacy asset sales. The new management team under CEO Jonathan Violin will advance lead candidate KRSA-028 toward Phase 1 data expected mid-2027. This is a thesis-altering event: the company has gone from a near-bankrupt shell to a funded clinical-stage biotech in a single transaction.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYCN was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.